- Home
- SYRA vs MBRX Comparison
SYRA vs MBRX Comparison
Compare SYRA & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRA
- MBRX
- Stock Information
- Founded
- SYRA 2020
- MBRX 2015
- Country
- SYRA United States
- MBRX United States
- Employees
- SYRA N/A
- MBRX N/A
- Industry
- SYRA Other Specialty Stores
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SYRA Industrials
- MBRX Health Care
- Exchange
- SYRA Nasdaq
- MBRX Nasdaq
- Market Cap
- SYRA 4.9M
- MBRX 5.1M
- IPO Year
- SYRA 2023
- MBRX 2016
- Fundamental
- Price
- SYRA $0.45
- MBRX $1.15
- Analyst Decision
- SYRA
- MBRX Strong Buy
- Analyst Count
- SYRA 0
- MBRX 2
- Target Price
- SYRA N/A
- MBRX $24.00
- AVG Volume (30 Days)
- SYRA 4.9M
- MBRX 38.4K
- Earning Date
- SYRA 03-24-2025
- MBRX 03-21-2025
- Dividend Yield
- SYRA N/A
- MBRX N/A
- EPS Growth
- SYRA N/A
- MBRX N/A
- EPS
- SYRA N/A
- MBRX N/A
- Revenue
- SYRA $7,741,558.00
- MBRX N/A
- Revenue This Year
- SYRA $47.74
- MBRX N/A
- Revenue Next Year
- SYRA N/A
- MBRX N/A
- P/E Ratio
- SYRA N/A
- MBRX N/A
- Revenue Growth
- SYRA 35.47
- MBRX N/A
- 52 Week Low
- SYRA $0.34
- MBRX $0.40
- 52 Week High
- SYRA $8.37
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- SYRA 46.92
- MBRX 31.81
- Support Level
- SYRA $0.37
- MBRX $1.33
- Resistance Level
- SYRA $0.55
- MBRX $1.82
- Average True Range (ATR)
- SYRA 0.07
- MBRX 0.13
- MACD
- SYRA -0.01
- MBRX -0.02
- Stochastic Oscillator
- SYRA 31.23
- MBRX 13.17
About SYRA Syra Health Corp.
Syra Health Corp is a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. The company leverages deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. It strives to offer comprehensive end-to-end solutions in health education services, population health management, behavioral and mental health, healthcare workforce and digital health.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.